162 related articles for article (PubMed ID: 16786320)
21. Volume-based quantitative FDG PET/CT metrics and their association with optimal debulking and progression-free survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery.
Vargas HA; Burger IA; Goldman DA; Miccò M; Sosa RE; Weber W; Chi DS; Hricak H; Sala E
Eur Radiol; 2015 Nov; 25(11):3348-53. PubMed ID: 25916387
[TBL] [Abstract][Full Text] [Related]
22. Usefulness of FDG PET for assessment of early recurrent epithelial ovarian cancer.
Cho SM; Ha HK; Byun JY; Lee JM; Kim CJ; Nam-Koong SE; Lee JM
AJR Am J Roentgenol; 2002 Aug; 179(2):391-5. PubMed ID: 12130439
[TBL] [Abstract][Full Text] [Related]
23. (F-18) fluorodeoxyglucose positron emission tomography as a predictor of pathologic grade and other prognostic variables in bone and soft tissue sarcoma.
Folpe AL; Lyles RH; Sprouse JT; Conrad EU; Eary JF
Clin Cancer Res; 2000 Apr; 6(4):1279-87. PubMed ID: 10778952
[TBL] [Abstract][Full Text] [Related]
24. Impact of positron emission tomography/computed tomography in the management of patients with epithelial ovarian carcinoma after treatment.
Nasu K; Abe W; Takai N; Tomonari K; Narahara H
Arch Gynecol Obstet; 2011 May; 283(5):1121-6. PubMed ID: 20574659
[TBL] [Abstract][Full Text] [Related]
25. [F-18]Fluorodeoxyglucose positron emission tomography can predict pathological tumor stage and proliferative activity determined by Ki-67 in clinical stage IA lung adenocarcinomas.
Watanabe K; Nomori H; Ohtsuka T; Naruke T; Ebihara A; Orikasa H; Yamazaki K; Uno K; Kobayashi T; Goya T
Jpn J Clin Oncol; 2006 Jul; 36(7):403-9. PubMed ID: 16782729
[TBL] [Abstract][Full Text] [Related]
26. Benefits of fluorine-18 fludeoxyglucose positron emission tomography in secondary cytoreductive surgery for patients with recurrent epithelial ovarian cancer.
Peng P; Zhu ZH; Zhong ZJ; Zheng K; Yang JX; Cao DY; Shen K
Br J Radiol; 2015 Aug; 88(1052):20150109. PubMed ID: 25989698
[TBL] [Abstract][Full Text] [Related]
27. [Clinical impact of FDG-PET in patients with suspected recurrent ovarian cancer].
Cuenca Cuenca JI; Borrego Dorado I; Vázquez Albertino R; Gómez Camarero P; Sanz Viedma S; Fernández López R
Rev Esp Med Nucl; 2008; 27(6):411-7. PubMed ID: 19094899
[TBL] [Abstract][Full Text] [Related]
28. Role of FDG-PET in the evaluation and staging of hepatocellular carcinoma with comparison of tumor size, AFP level, and histologic grade.
Wolfort RM; Papillion PW; Turnage RH; Lillien DL; Ramaswamy MR; Zibari GB
Int Surg; 2010; 95(1):67-75. PubMed ID: 20480845
[TBL] [Abstract][Full Text] [Related]
29. 18-Fluorine fluorodeoxyglucose positron emission tomography in the pretreatment evaluation of thymic epithelial neoplasms: a metabolic biopsy confirmed by Ki-67 expression.
Viti A; Bertolaccini L; Cavallo A; Fortunato M; Bianchi A; Terzi A
Eur J Cardiothorac Surg; 2014 Sep; 46(3):369-74; discussion 374. PubMed ID: 24585679
[TBL] [Abstract][Full Text] [Related]
30. 18F-FDG Uptake in Well-Differentiated Neuroendocrine Tumors Correlates with Both Ki-67 and VHL Pathway Inactivation.
Bucau M; Laurent-Bellue A; Poté N; Hentic O; Cros J; Mikail N; Rebours V; Ruszniewski P; Lebtahi R; Couvelard A
Neuroendocrinology; 2018; 106(3):274-282. PubMed ID: 28803235
[TBL] [Abstract][Full Text] [Related]
31. FDG-PET/CT to predict optimal primary cytoreductive surgery in patients with advanced ovarian cancer: preliminary results.
Alessi A; Martinelli F; Padovano B; Serafini G; Lorusso D; Lorenzoni A; Ditto A; Lecce F; Mira M; Donfrancesco C; Raspagliesi F; Crippa F
Tumori; 2016; 102(1):103-7. PubMed ID: 26350201
[TBL] [Abstract][Full Text] [Related]
32. Survival time prediction in patients with high-grade serous ovarian cancer based on
He D; Zhang X; Chang Z; Liu Z; Li B
BMC Cancer; 2024 Mar; 24(1):337. PubMed ID: 38475819
[TBL] [Abstract][Full Text] [Related]
33. Novel perioperative imaging with 18F-FDG PET/CT and intraoperative 18F-FDG detection using a handheld gamma probe in recurrent ovarian cancer.
Cohn DE; Hall NC; Povoski SP; Seamon LG; Farrar WB; Martin EW
Gynecol Oncol; 2008 Aug; 110(2):152-7. PubMed ID: 18539314
[TBL] [Abstract][Full Text] [Related]
34. Quantitative metabolic parameters measured on F-18 FDG PET/CT predict survival after relapse in patients with relapsed epithelial ovarian cancer.
Kim CY; Jeong SY; Chong GO; Son SH; Jung JH; Kim DH; Lee SW; Ahn BC; Lee J
Gynecol Oncol; 2015 Mar; 136(3):498-504. PubMed ID: 25557270
[TBL] [Abstract][Full Text] [Related]
35. Correlation between (18)F-FDG uptake on PET/CT and prognostic factors in triple-negative breast cancer.
Koo HR; Park JS; Kang KW; Han W; Park IA; Moon WK
Eur Radiol; 2015 Nov; 25(11):3314-21. PubMed ID: 25903708
[TBL] [Abstract][Full Text] [Related]
36. Effect of clinicopathologic factors on visibility of colorectal polyps with FDG PET.
Nakajo M; Jinnouchi S; Tashiro Y; Shirahama H; Sato E; Koriyama C; Nakajo M
AJR Am J Roentgenol; 2009 Mar; 192(3):754-60. PubMed ID: 19234274
[TBL] [Abstract][Full Text] [Related]
37. Diagnostic accuracy of 18F-FDG PET/CT in characterizing ovarian lesions and staging ovarian cancer: correlation with transvaginal ultrasonography, computed tomography, and histology.
Castellucci P; Perrone AM; Picchio M; Ghi T; Farsad M; Nanni C; Messa C; Meriggiola MC; Pelusi G; Al-Nahhas A; Rubello D; Fazio F; Fanti S
Nucl Med Commun; 2007 Aug; 28(8):589-95. PubMed ID: 17625380
[TBL] [Abstract][Full Text] [Related]
38. A prospective comparison of integrated FDG-PET/contrast-enhanced CT and contrast-enhanced CT for pretreatment imaging of advanced epithelial ovarian cancer.
Hynninen J; Kemppainen J; Lavonius M; Virtanen J; Matomäki J; Oksa S; Carpén O; Grénman S; Seppänen M; Auranen A
Gynecol Oncol; 2013 Nov; 131(2):389-94. PubMed ID: 23994535
[TBL] [Abstract][Full Text] [Related]
39. Whole body positron emission tomography with 18F-fluoro-2-deoxyglucose for the detection of recurrent ovarian cancer.
Yen RF; Sun SS; Shen YY; Changlai SP; Kao A
Anticancer Res; 2001; 21(5):3691-4. PubMed ID: 11848544
[TBL] [Abstract][Full Text] [Related]
40. Prognostic implication of the metastatic lesion-to-ovarian cancer standardised uptake value ratio in advanced serous epithelial ovarian cancer.
Chung HH; Lee M; Kim HS; Kim JW; Park NH; Song YS; Cheon GJ
Eur Radiol; 2017 Nov; 27(11):4510-4515. PubMed ID: 28593431
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
